# First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients

> **NCT05964361** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University Hospital, Antwerp** · enrollment: 10 (estimated)

## Conditions studied

- Esophageal Cancer
- Pancreas Cancer
- Ovarian Cancer
- Liver Cancer

## Interventions

- **BIOLOGICAL:** IL15-transpresenting WT1-targeted Dendritic Cell Vaccine

## Key facts

- **NCT ID:** NCT05964361
- **Lead sponsor:** University Hospital, Antwerp
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-06
- **Primary completion:** 2025-09-28
- **Final completion:** 2025-09-28
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-04-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05964361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05964361, "First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05964361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*